The Current Ratio as of November 2024 (TTM) for Avidity Biosciences, Inc. (RNA) is 17.76

According to Avidity Biosciences, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 17.76. This represents a change of 32.57% compared to the average of 13.40 of the last 4 quarters.

Avidity Biosciences, Inc. (RNA) Historical Current Ratio (quarterly & annually)

How has RNA Current Ratio performed in the past?

The mean historical Current Ratio of Avidity Biosciences, Inc. over the last ten years is 11.04. The current 17.76 Current Ratio has changed 15.99% with respect to the historical average. Over the past ten years (40 quarters), RNA's Current Ratio was at its highest in in the June 2020 quarter at 30.45. The Current Ratio was at its lowest in in the March 2019 quarter at 0.

Avidity Biosciences, Inc. (RNA) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Avidity Biosciences, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Avidity Biosciences, Inc. (RNA) Average Current Ratio

How has RNA Current Ratio performed in the past?

The current Current Ratio of Avidity Biosciences, Inc. (RNA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Avidity Biosciences, Inc. (RNA) Current Ratio vs. Peers

How is RNA’s Current Ratio compared to its peers?

Avidity Biosciences, Inc.’s Current Ratio is greater than TCR2 Therapeutics Inc. (2.77), greater than Revolution Medicines, Inc. (14.24), greater than Black Diamond Therapeutics, Inc. (5.55), greater than Atreca, Inc. (1.58), greater than Passage Bio, Inc. (5.15), greater than Akero Therapeutics, Inc. (17.25), greater than Protagonist Therapeutics, Inc. (10.70), greater than Stoke Therapeutics, Inc. (5.09), greater than IGM Biosciences, Inc. (5.22), greater than Cerevel Therapeutics Holdings, Inc. (10.22), less than Cullinan Oncology, Inc. (24.46), greater than Mineralys Therapeutics, Inc. (8.55), greater than Day One Biopharmaceuticals, Inc. (14.62), greater than SpringWorks Therapeutics, Inc. (6.16), less than Relay Therapeutics, Inc. (18.42), greater than Pliant Therapeutics, Inc. (10.26), greater than Arvinas, Inc. (4.17),

Build a custom stock screener for Avidity Biosciences, Inc. (RNA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Avidity Biosciences, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Avidity Biosciences, Inc. (RNA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Avidity Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.